Cidara Therapeutics and Wuxi XDC Expand Collaboration for IND-Enabling CMC Development
Thursday, February 02, 2023
Cidara Therapeutics announced an expansion of their existing collaboration under which Wuxi XDC will provide investigational new drug (ind)-enabling chemistry, manufacturing and controls (CMC) development services for cidara’s CD73 oncology DFC programme.
The expansion of this relationship by combining WuXi XDC’s core competencies in bioconjugates manufacturing with the expertise in DFCs will advance the manufacturing of first-in-class CD73 oncology DFC.
This expanded partnership builds a strong testament to the industry-leading capabilities and expertise. The commitment to build an innovation ecosystem for bioconjugates by offering global open-access technology platforms with premier quality standards will support the partners worldwide to build innovative ideas into transformative new treatments for patients.
